ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2521

Immunoglobulin G Fc Receptor Activity in Vivo Is Under Complement Control

Eveline Y. Wu1, Haixiang Jiang2, C. Garren Hester3 and Michael M. Frank2, 1DUMC Box 3212, Duke Univ Med Ctr, Durham, NC, 2Pediatrics, Duke Univ Med Ctr, Durham, NC, 3Duke Univ Med Ctr, Durham, NC

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: C1q, Fc receptors and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Immunoglobulin G receptors (FcγR) are critical in the development of autoimmunity and pathogenesis of immune complex (IC) diseases. Although ICs activate complement, contributing to tissue damage, it is reported complement does not affect IC interaction with FcγR. We have re-explored this issue and find complement has a major impact on IC interaction with FcγR. Specifically, the classical pathway (CP) down-regulates and the alternative pathway (AP) promotes IC binding to FcγR. We performed reverse passive Arthus reactions, a model of IC-mediated cutaneous vasculitis, in normal C57Bl/6 mice and mice genetically deficient in complement proteins C1q, C4 and Factor B. It is also reported that complement does not contribute to Arthus reactions in mice, unlike in other animals. We hypothesized the CP, rather than contributing to vasculitis, down-regulates tissue injury caused by IC interaction with activating FcγR; therefore, its absence (C1q-/- and C4-/-) would enhance cutaneous vasculitis, while absence of the AP (Factor B-/-) would diminish cutaneous vasculitis.

Methods: Sedated and shaved mice (normal, C1q-/-, C4-/-, and Factor B-/-) were injected intradermally with 20 µl of PBS alone on one side and affinity purified rabbit anti-bovine serum albumin (BSA) IgG 5 µg in PBS on the opposite side. Immediately following, BSA 100 µg and 125Iodine-labeled BSA 1.25 µg in PBS containing 1% Evans blue was injected intravenously. After 4 hours, mice were sacrificed and the extravasated blue spot and control injection spot were dissected and weighed. Radioactivity per specimen weight (cpm/gm) of treated skin was divided by that of control skin to determine an Arthus index (AI) for each mouse. Arthus indices were first analyzed by Kruskal-Wallis ranked test, followed by Mann-Whitney U test to evaluate for significant differences in median AI. P values less than 0.05 were considered significant.

Results: Complement activation strongly influenced the degree of cutaneous vasculitis in mice (Fig. 1, p=0.0013). C1q-/- (mean AI 3.8±0.7, p=0.0125) and C4-/- (mean AI 4.7±2.3, p=0.0504) mice exhibited more extensive vasculitis than normal animals (mean AI 2.6±1.2).  Conversely, Factor B deficient (mean AI 1.4±0.5, p=0.0553) mice trended towards significantly reduced vasculitis compared to normal animals.

Conclusion: Cutaneous vasculitis is significantly greater in mice deficient in CP complement proteins and appeared reduced in mice deficient in AP complement proteins. Our results are the first to provide physiologic evidence in vivo that complement critically influences IC and FcγR mediated inflammation. They also refute previous data suggesting complement possesses no role in Arthus-induced vasculitis in mice. They may further our understanding of why individuals with CP defects are noted to have frequent signs of autoimmune pathology.

Fig 1: Reverse Passive Arthus Reactions


Disclosure:

E. Y. Wu,
None;

H. Jiang,
None;

C. G. Hester,
None;

M. M. Frank,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunoglobulin-g-fc-receptor-activity-in-vivo-is-under-complement-control/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology